Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Gives Up On Galapagos's Filgotinib In RA

Belgian Biotech's Stock Battered

Executive Summary

A disappointing meeting with the FDA means "we no longer see a viable path to US approval in this indication,” said Gilead CEO Daniel O'Day, as Galapagos assumes sole responsibility for the commercialization of the JAK inhibitor in Europe.

You may also be interested in...



Galapagos Loses Potential Ticket To America As Crohns Trial Flops

The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.

Gilead Goes Full Steam Ahead In Oncology With Big Lung Cancer Push

The company has eight lung cancer trials running and plans for nine by the end of the year, including five with Trodelvy alone. Gilead is also looking ahead to an FDA verdict on lenacapavir.

Galapagos Keeps Analysts Guessing About Future Plans

Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel